Blog

The #Path2Cures – What They’re Saying in Beantown


08.27.14

The Energy and Commerce Committee’s 21st Century Cures effort has been moving across America this month with various roundtables and events. This afternoon, Reps. Bob Latta (R-OH) and Bill Johnson (R-OH) will host an event in Columbus, Ohio, and on Friday, Health Subcommittee Chairman Joe Pitts (R-PA) will host a roundtable in Lancaster, Pennsylvania, with committee Chairman Fred Upton (R-MI), Health Subcommittee Vice Chairman Michael C. Burgess, M.D. (R-TX), and Subcommittee Ranking Member Frank Pallone (D-NJ) that will also feature the heads of the NIH and FDA. Many health care professionals, innovators, researchers, patients, and advocacy groups, such as South Florida’s Parkinson’s Action Network, have been active and expressed strong support for the effort.

Earlier this week, Health Subcommittee Vice Chairman Michael C. Burgess, M.D. (R-TX) participated in a roundtable hosted by the Manhattan Institute in Boston, Massachusetts on “Building a 21st Century Health Care System: Aligning Policy, Accelerating Cures, Delivering Hope.” “The Pink Sheet” DAILY has the recap of the Boston event, and here’s a sampling of what folks are saying:

Jeff Allen, Friends of Cancer Research executive director: 

 “You know Chairman Upton has made this his key priority. He’s very passionate about it, he’s shown this not only in the time that the committee has put forth to discussing this but even when given the opportunity to hear him speak about this personally it’s clear that this is a personal priority for him.”

 

Robert Popovian, Pfizer Inc.’s Senior Director for Advocacy & Professional Relations:

 

“We cannot just have this snapshot of legislative efforts and then let’s put it aside and let’s run to something else. I think this is a longer-term issue that we need to deal with…It’s heartwarming to see that they are actually taking a global view of this thing, rather than a siloed very short term view of trying to fix something.”

 

Ken Kaitin, Tuft’s CSDD Director:

“The landscape for innovation is changing dramatically. … When they passed the first user fee legislation in 1992 there were the regulators and there were the developers, the drug sponsors. Now everything is a consortium of some sort to bring products, it’s a partnership model and we’re moving more and more in that direction…Any initiative that’s going to try to improve the facility to get drugs on the market is going to have to encompass those stakeholders in a way that didn’t exist in the past and that’s why these types of discussions are so important.”

 

Groups also joined the discussion on Twitter:

Join the conversation on Twitter and Facebook using #Path2Cures. Learn more about the effort here.

###


Subcommittees
Health (113th Congress)
Blog